1.Prognostic value of Sox2 expression in digestive tract cancers: A meta-analysis.
Xiao-Ming DU ; Liu-Hua WANG ; Xiao-Wen CHEN ; Yi-Xiao LI ; Yu-Cong LI ; Yu-Wen CAO
Journal of Huazhong University of Science and Technology (Medical Sciences) 2016;36(3):305-312
The aim of the present study was to accurately evaluate the association of Sox2 expression with the survival of patients with digestive tract cancers. Relevant literatures were identified by comprehensively searching databases including the Pubmed, Embase, CBMdisc, and Wanfang (up to October 2014). A meta-analysis was performed to clarify the association between Sox2 expression and overall survival or clinicopathological parameters of patients with digestive tract cancers (esophageal, gastric, and colorectal cancers). The results showed a significant association between high Sox2 expression and poor overall survival in patients with digestive tract carcinomas (HR=1.55, 95% CI=1.04-2.31), especially for patients with esophageal cancer (HR=2.04, 95%CI=1.30-3.22), colorectal cancer (HR=1.40, 95% CI=1.04-1.89), and digestive tract adenocarcinoma (HR=1.80, 95% CI=1.12-2.89), for Europeans (HR=1.98, 95% CI=1.44-2.71) or patients who did not receive neoadjuvant treatment (HR=1.73, 95% CI=1.10-2.72). Furthermore, Sox2 over-expression was highly correlated with vascular invasion (OR=1.86, 95% CI=1.25-2.77) and poor differentiation (OR=1.88, 95% CI=1.14-3.08), especially in esophageal and colorectal cancers. In conclusion, Sox2 expression may serve as a novel prognostic factor for patients with digestive tract cancers. Over-expression of Sox2 that is correlated with vascular invasion and poor differentiation suggests poor outcomes of patients with digestive tract cancers.
Antineoplastic Agents
;
therapeutic use
;
Biomarkers, Tumor
;
genetics
;
metabolism
;
Colorectal Neoplasms
;
diagnosis
;
drug therapy
;
mortality
;
pathology
;
Esophageal Neoplasms
;
diagnosis
;
drug therapy
;
mortality
;
pathology
;
Gastrointestinal Tract
;
metabolism
;
pathology
;
Gene Expression
;
Humans
;
Neoadjuvant Therapy
;
methods
;
Neoplasm Grading
;
Neoplasms, Vascular Tissue
;
diagnosis
;
drug therapy
;
mortality
;
secondary
;
Prognosis
;
SOXB1 Transcription Factors
;
genetics
;
metabolism
;
Stomach Neoplasms
;
diagnosis
;
drug therapy
;
mortality
;
pathology
;
Survival Analysis
2.Clinical effect of intraoperative peritoneal hyperthermic chemotherapy for advanced gastric cancer.
Zheng-gang ZHU ; Rui TANG ; Min YAN ; Jun CHEN ; Qiu-meng YANG ; Shen LI ; Xue-xin YAO ; Jun ZHANG ; Hao-ran YIN ; Yan-zhen LIN
Chinese Journal of Gastrointestinal Surgery 2006;9(1):26-30
OBJECTIVETo investigate the clinical effect of intraoperative peritoneal hyperthermic chemotherapy (IPHC) for advanced gastric cancer (AGC).
METHODSA total of 118 AGC patients with serosal invasion were enrolled in this study from 1998 to 2001. Among these cases, 96 patients without macroscopic peritoneal metastases were selected for prophylactic study, including 42 cases with IPHC and 54 cases without IPHC as control. Other 22 patients with macroscopic peritoneal metastases were selected for therapeutic study, including 10 cases with IPHC and 12 without IPHC. Postoperative survival rate and peritoneal recurrence were compared.
RESULTSFor prophylactic study, the 1, 2 and 4 years survival rates were 85.7%, 81.0% and 63.9% respectively in the patients with IPHC,significantly higher than 77.3%, 61.0% and 50.8% in the patients without IPHC. Cox ratio hazard model revealed that IPHC procedure was an independent prognostic factor. More patients in the control group suffered from peritoneal recurrence than those in IPHC group (34.7% vs 10.3%). For therapeutic study,the median survival period of the patients with IPHC was 10 months, higher than 5 months in the patients without IPHC. The overall 1, 2, 4 year survival rates were 76.9%, 69.2%, 55.2% respectively in all cases with IPHC, higher than 66.2%, 49.7%, 41.4% in the cases without IPHC.
CONCLUSIONIPHC procedure can improve the prognosis of AGC patients with serosal invasion, reduce the risk for peritoneal recurrence, and is an independent prognostic factor.
Adult ; Aged ; Chemotherapy, Cancer, Regional Perfusion ; methods ; Female ; Follow-Up Studies ; Humans ; Hyperthermia, Induced ; Male ; Middle Aged ; Neoplasm Metastasis ; Neoplasm Staging ; Peritoneal Neoplasms ; drug therapy ; secondary ; Prognosis ; Stomach Neoplasms ; drug therapy ; mortality ; pathology ; Survival Rate ; Treatment Outcome
3.Oxaliplatin and Leucovorin Plus Fluorouracil Versus Irinotecan and Leucovorin Plus Fluorouracil Combination Chemotherapy as a First-line Treatment in Patients with Metastatic or Recurred Gastric Adenocarcinoma.
Sun Hyung KANG ; Jeong Il KIM ; Hee Seok MOON ; Seok Hyun KIM ; Jae Kyu SUNG ; Byung Seok LEE ; Hyun Yong JEONG
The Korean Journal of Gastroenterology 2010;55(1):26-32
BACKGROUND/AIMS: We performed retrospective study in order to compare oxaliplatin, leucovorin, and fluorouracil (FOLFOX) versus irinotecan, leucovorin, and fluorouracil (FOLFIRI) in recurred or metastatic gastric adenocarcinoma. METHODS: We investigated 56 patients who were diagnosed with recurred or metastatic gastric adenocarcinoma in a single center during march, 2003 to march, 2008. The patients received either FOLFOX or FOLFIRI chemotherapy. RESULTS: There were no significant difference between the Oxaliplatin group (30 patients) and Irinotecan group (26 patients) in sex, age, and ECOG performance (p>0.05). Oxaliplatin group showed 1 case of CR (3.3%) and 12 cases of PR (40%), making the response rate 43.3%. Irinotecan group showed CR in 2 cases (7.7%) and PR in 10 cases (38.5%), making the response rate 46.2%. The median value of time to progression was 4 months in the oxlaplatin group and 4.5 months in the irinotecan group. The overall survival showed no significant difference (p=0.784), with the irinotecan group (9.7 months) being slightly longer than the Oxaliplatin group (8.3 months). Grade 3/4 neutropenia occurred similarly in both groups (4 cases in the oxalplatin group, 9 in the irinotecan group). CONCLUSIONS: Both combination treatment can be used safely and effectively in recurred or metastatic gastric adenocarcinoma.
Adenocarcinoma/*drug therapy/mortality/secondary
;
Adult
;
Aged
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Camptothecin/analogs & derivatives/therapeutic use
;
Female
;
Fluorouracil/therapeutic use
;
Humans
;
Leucovorin/therapeutic use
;
Male
;
Middle Aged
;
Neoplasm Recurrence, Local/drug therapy
;
Organoplatinum Compounds/therapeutic use
;
Recurrence
;
Retrospective Studies
;
Stomach Neoplasms/*drug therapy/mortality
;
Survival Analysis
4.Epirubicin, Cisplatin, and Protracted Venous Infusion of 5-Fluorouracil for Advanced Gastric Carcinoma.
Eun Kyung CHO ; Woon Ki LEE ; Do Yoon LIM ; Soo Mee BANG ; Dong Kyun PARK ; Yeon Ho PARK ; Oh Sang KWON ; Duck Joo CHOI ; Dong Bok SHIN ; Jae Hoon LEE ; Tae Hoon LEE
Journal of Korean Medical Science 2002;17(3):348-352
To evaluate the activity and safety of a combination chemotherapy with epirubicin, cisplatin, and a protracted venous infusion of 5-fluorouracil (ECF) in unresectable or metastatic gastric cancer, a phase II study was performed. Thirty-five chemotherapy-naive patients were given ECF. Epirubicin (50 mg/m2 intravenous, IV) and cisplatin (60 mg/m2 IV) were administered every three weeks during a continuous intravenous infusion of 5-fluorouracil (250 mg/m2 /day) using infusion pump. One complete response and 19 partial responses (response rate=62%) were achieved. Eight patients remained stable, whereas in four patients the disease progressed. The median duration of response was 22 weeks (95% confidence interval, 18-27 weeks). The median survival for all patients was 10 months (95% confidence interval, 6-14 months), with a 1-yr survival rate of 40%. A total of 184 cycles of chemotherapy were administered. Grade 3 or 4 emesis occurred in 3%, mucositis in 2%, anemia in 10%, and leukopenia in 3% of the cycles. Central venous catheter complications that required line removal occurred in 37% (n=13) of the patients. No patient died of toxicity. Overall, the ECF regimen showed high anti-tumor activity with a tolerable toxicity pattern.
Adult
;
Aged
;
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects
;
Cisplatin/*administration & dosage/adverse effects
;
Epirubicin/*administration & dosage/adverse effects
;
Female
;
Fluorouracil/*administration & dosage/adverse effects
;
Humans
;
Infusion Pumps
;
Infusions, Intravenous
;
Male
;
Middle Aged
;
Stomach Neoplasms/*drug therapy/mortality/secondary
;
Survival Analysis